Sugi Predict

Sugi Predict / Compounds / SCHEMBL1316680

SCHEMBL1316680

SCHEMBL1316680

COc1ccc(OC(=O)c2ccc(Cl)cc2)cc1-c1ccc2c(c1COc1cc(F)ccc1C)C(C)=CC(C)(C)N2

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ IL6 P05231 8/20 0.47
▸ LMNA P02545 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PGR P06401 7/20 0.39
▸ NR3C1 P04150 5/20 0.37
▸ AR P10275 2/20 0.36
▸ NR3C2 P08235 1/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ ESR2 Q92731 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1315710 0.96 IL6 (0.48) IL6LMNATP53MAPTHTT
SCHEMBL1314521 0.93 IL6 (0.48) IL6LMNATP53MAPTHTT
SCHEMBL1314844 0.92 IL6 (0.46) IL6LMNATP53MAPTHTT
SCHEMBL1315697 0.91 IL6 (0.47) IL6LMNATP53MAPTHTT
SCHEMBL1314431 0.91 IL6 (0.50) IL6LMNATP53MAPTHTT
SCHEMBL1315635 0.90 IL6 (0.49) IL6LMNATP53MAPTHTT
SCHEMBL1315152 0.90 IL6 (0.49) IL6LMNATP53MAPTHTT
SCHEMBL1315792 0.90 IL6 (0.49) IL6LMNATP53MAPTHTT
SCHEMBL1314481 0.89 IL6 (0.48) IL6LMNATP53MAPTHTT
SCHEMBL1313832 0.89 IL6 (0.48) IL6LMNATP53MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440660-B2 Method for treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-05-14 — — US disclosed
US-8440660-B2 Method for treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-05-14 — — US disclosed
US-8440660-B2 Method for treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-05-14 — — US disclosed
EP-2085387-B1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO LTD (JP) 2013-04-10 — — EP disclosed
US-20110275620-A1 Method for preventing or treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-10 — — US disclosed
US-20110275620-A1 Method for preventing or treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-10 — — US disclosed
US-20110275620-A1 Method for preventing or treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-10 — — US disclosed
US-8008496-B2 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-08-30 — — US disclosed
US-8008496-B2 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-08-30 — — US disclosed
US-8008496-B2 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-08-30 — — US disclosed
US-20100056504-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER- INTRODUCED PHENYL GROUP AS SUBSTITUENTS AYUMI PHARMACEUTICAL CORPORATION (JP) 2010-03-04 — — US disclosed
US-20100056504-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER- INTRODUCED PHENYL GROUP AS SUBSTITUENTS AYUMI PHARMACEUTICAL CORPORATION (JP) 2010-03-04 — — US disclosed
US-20100056504-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER- INTRODUCED PHENYL GROUP AS SUBSTITUENTS AYUMI PHARMACEUTICAL CORPORATION (JP) 2010-03-04 — — US disclosed
EP-2085387-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 — — EP disclosed
EP-2085387-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056504-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER- INTRODUCED PHENYL GROUP AS SUBSTITUENTS NR3C1, NR3C2, NR5A1 IL6 2625/4885LMNA 4440/4885TP53 4413/4885
US-20110275620-A1 Method for preventing or treating a disease related to the glucocorticoid receptor NR3C1, NR3C2, NR5A1 IL6 1770/4885LMNA 2024/4885TP53 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.